These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26916391)

  • 1. JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus.
    Wenzel J; van Holt N; Maier J; Vonnahme M; Bieber T; Wolf D
    J Invest Dermatol; 2016 Jun; 136(6):1281-1283. PubMed ID: 26916391
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency.
    Briand C; Frémond ML; Bessis D; Carbasse A; Rice GI; Bondet V; Duffy D; Chatenoud L; Blanche S; Crow YJ; Neven B
    Ann Rheum Dis; 2019 Mar; 78(3):431-433. PubMed ID: 30282666
    [No Abstract]   [Full Text] [Related]  

  • 3. JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus.
    Klaeschen AS; Wolf D; Brossart P; Bieber T; Wenzel J
    Exp Dermatol; 2017 Aug; 26(8):728-730. PubMed ID: 27892610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
    Goker Bagca B; Biray Avci C
    Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib.
    Becker H; Engelhardt M; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
    Vaddi K; Sarlis NJ; Gupta V
    Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.
    Fetter T; Smith P; Guel T; Braegelmann C; Bieber T; Wenzel J
    Front Immunol; 2020; 11():344. PubMed ID: 32194562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.
    Wei Q; Xu J
    Blood; 2024 Jul; 144(2):238. PubMed ID: 38990537
    [No Abstract]   [Full Text] [Related]  

  • 9. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
    Ostojic A; Vrhovac R; Verstovsek S
    Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.
    Frémond ML; Rodero MP; Jeremiah N; Belot A; Jeziorski E; Duffy D; Bessis D; Cros G; Rice GI; Charbit B; Hulin A; Khoudour N; Caballero CM; Bodemer C; Fabre M; Berteloot L; Le Bourgeois M; Reix P; Walzer T; Moshous D; Blanche S; Fischer A; Bader-Meunier B; Rieux-Laucat F; Crow YJ; Neven B
    J Allergy Clin Immunol; 2016 Dec; 138(6):1752-1755. PubMed ID: 27554814
    [No Abstract]   [Full Text] [Related]  

  • 11. Ruxolitinib for myelofibrosis.
    Diamantidis MD
    N Engl J Med; 2012 May; 366(21):2031; author reply 2032-4. PubMed ID: 22621633
    [No Abstract]   [Full Text] [Related]  

  • 12. Ruxolitinib for myelofibrosis.
    Koschmieder S; Koppelle A; Seifert H
    N Engl J Med; 2012 May; 366(21):2031-2; author reply 2032-4. PubMed ID: 22621634
    [No Abstract]   [Full Text] [Related]  

  • 13. Ruxolitinib for myelofibrosis.
    Haznedaroglu IC
    N Engl J Med; 2012 May; 366(21):2032; author reply 2032-5. PubMed ID: 22621635
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
    de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
    Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
    Hermans MAW; Schrijver B; van Holten-Neelen CCPA; Gerth van Wijk R; van Hagen PM; van Daele PLA; Dik WA
    Clin Exp Allergy; 2018 Nov; 48(11):1412-1420. PubMed ID: 29939445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.
    Wilkins BS; Radia D; Woodley C; Farhi SE; Keohane C; Harrison CN
    Haematologica; 2013 Dec; 98(12):1872-6. PubMed ID: 24056820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.
    Sapre M; Tremblay D; Wilck E; James A; Leiter A; Coltoff A; Koshy AG; Kremyanskaya M; Hoffman R; Mascarenhas JO; Gallagher EJ
    Sci Rep; 2019 Nov; 9(1):16609. PubMed ID: 31719581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case of disseminated molluscum contagiosum caused by ruxolitinib, a Janus kinase 1 and 2 inhibitor.
    Kinoshita M; Ogawa Y; Kawamura T; Kirito K; Shimada S
    J Dermatol; 2016 Nov; 43(11):1387-1388. PubMed ID: 27060215
    [No Abstract]   [Full Text] [Related]  

  • 19. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
    Gomez-Arteaga A; Margolskee E; Wei MT; van Besien K; Inghirami G; Horwitz S
    Leuk Lymphoma; 2019 Jul; 60(7):1626-1631. PubMed ID: 30997845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.